Relay Therapeutics Hits New 52-Week High of $17.70, Up 131.61%

Relay Therapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 17.70 on June 23, 2026. This achievement marks a remarkable increase in the stock's performance, with a year-over-year gain of 131.61%, significantly outpacing the S&P 500's performance of 22.24% during the same period. The company's market capitalization stands at USD 1,716 million, reflecting its position within the small-cap category. Despite its impressive stock performance, Relay Therapeutics is currently operating at a loss, as indicated by its negative price-to-earnings ratio and return on equity of -48.76%. The company does not offer a dividend, and its debt-to-equity ratio is reported at -0.97, suggesting a unique financial structure. With a price-to-book ratio of 3.03, Relay Therapeutics continues to navigate the competitive landscape of the biotechnology industry, showcasing its resilience and growth potential as it reaches this notable price point.